National Cooperative Growth Study in CKD
Overview
The purpose of this study is to learn whether growth hormone being administered to children with Chronic Kidney Disease is effective and if it has any side effects.
Full Title of Study: “National Cooperative Growth Study of Nutropin AQ, Nutropin, Protropin, and Nutropin Depot in Children With Growth Failure Due to Chronic Renal Insufficiency (CRI) or End-Stage Renal Disease (ESRD)”
Study Type
- Study Type: Observational
- Study Design
- Time Perspective: Prospective
- Study Primary Completion Date: February 2010
Clinical Trial Outcome Measures
Primary Measures
- The primary outcome measures of the NCGS are ongoing safety and efficacy of Genentech GH preparations in pediatric growth disorders for which GH is initiated.
- Time Frame: per the study, the pt will be on GH treatement until the physician instructs them to stop
Participating in This Clinical Trial
Inclusion Criteria
- Must be a patient of the UC Davis Medical Center pediatric clinic with Chronic Kidney Disease Exclusion Criteria:
- Greater than 18 years old – Not a patient at the UC Davis Medical Center pediatric clinic
Gender Eligibility: All
Minimum Age: 1 Day
Maximum Age: 18 Years
Are Healthy Volunteers Accepted: No
Investigator Details
- Lead Sponsor
- University of California, Davis
- Collaborator
- Genentech, Inc.
- Provider of Information About this Clinical Study
- Sponsor
- Overall Official(s)
- Lavjay Butani, M.D., Principal Investigator, University of California, Davis
Clinical trials entries are delivered from the US National Institutes of Health and are not reviewed separately by this site. Please see the identifier information above for retrieving further details from the government database.